EDWARDS LIFESCIENCES CORP (EW) Fundamental Analysis & Valuation

NYSE:EW • US28176E1082

Current stock price

79.76 USD
-1.77 (-2.17%)
Last:

This EW fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. EW Profitability Analysis

1.1 Basic Checks

  • In the past year EW was profitable.
  • EW had a positive operating cash flow in the past year.
  • EW had positive earnings in each of the past 5 years.
  • EW had a positive operating cash flow in each of the past 5 years.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

1.2 Ratios

  • EW's Return On Assets of 7.84% is amongst the best of the industry. EW outperforms 88.24% of its industry peers.
  • EW's Return On Equity of 10.38% is amongst the best of the industry. EW outperforms 83.96% of its industry peers.
  • EW's Return On Invested Capital of 12.01% is amongst the best of the industry. EW outperforms 91.98% of its industry peers.
  • EW had an Average Return On Invested Capital over the past 3 years of 13.04%. This is above the industry average of 9.12%.
Industry RankSector Rank
ROA 7.84%
ROE 10.38%
ROIC 12.01%
ROA(3y)18.26%
ROA(5y)18.16%
ROE(3y)24.41%
ROE(5y)25.04%
ROIC(3y)13.04%
ROIC(5y)15.54%
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • With an excellent Profit Margin value of 17.69%, EW belongs to the best of the industry, outperforming 92.51% of the companies in the same industry.
  • EW's Profit Margin has been stable in the last couple of years.
  • With an excellent Operating Margin value of 27.17%, EW belongs to the best of the industry, outperforming 95.72% of the companies in the same industry.
  • In the last couple of years the Operating Margin of EW has declined.
  • The Gross Margin of EW (78.01%) is better than 90.37% of its industry peers.
  • EW's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.17%
PM (TTM) 17.69%
GM 78.01%
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. EW Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EW is creating some value.
  • EW has less shares outstanding than it did 1 year ago.
  • EW has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for EW has been reduced compared to a year ago.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 11.12 indicates that EW is not in any danger for bankruptcy at the moment.
  • EW has a Altman-Z score of 11.12. This is amongst the best in the industry. EW outperforms 89.30% of its industry peers.
  • EW has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
  • EW's Debt to FCF ratio of 0.45 is amongst the best of the industry. EW outperforms 90.91% of its industry peers.
  • A Debt/Equity ratio of 0.06 indicates that EW is not too dependend on debt financing.
  • EW has a better Debt to Equity ratio (0.06) than 68.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.45
Altman-Z 11.12
ROIC/WACC1.36
WACC8.86%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.3 Liquidity

  • EW has a Current Ratio of 3.72. This indicates that EW is financially healthy and has no problem in meeting its short term obligations.
  • EW's Current ratio of 3.72 is in line compared to the rest of the industry. EW outperforms 59.89% of its industry peers.
  • EW has a Quick Ratio of 3.09. This indicates that EW is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.09, EW is in the better half of the industry, outperforming 65.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.09
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. EW Growth Analysis

3.1 Past

  • EW shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.29%.
  • EW shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.67% yearly.
  • The Revenue has grown by 10.86% in the past year. This is quite good.
  • The Revenue has been growing slightly by 6.70% on average over the past years.
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%

3.2 Future

  • EW is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.89% yearly.
  • The Revenue is expected to grow by 9.72% on average over the next years. This is quite good.
EPS Next Y17.69%
EPS Next 2Y14.79%
EPS Next 3Y14.05%
EPS Next 5Y12.89%
Revenue Next Year10.66%
Revenue Next 2Y10.24%
Revenue Next 3Y10.15%
Revenue Next 5Y9.72%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. EW Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 31.16, EW can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, EW is valued a bit cheaper than the industry average as 72.19% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.50. EW is around the same levels.
  • The Price/Forward Earnings ratio is 26.47, which means the current valuation is very expensive for EW.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EW indicates a somewhat cheap valuation: EW is cheaper than 74.87% of the companies listed in the same industry.
  • EW is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.62, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31.16
Fwd PE 26.47
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EW is valued a bit cheaper than 72.73% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, EW is valued a bit cheaper than the industry average as 75.40% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 34.45
EV/EBITDA 23.31
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of EW may justify a higher PE ratio.
  • EW's earnings are expected to grow with 14.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.76
PEG (5Y)4.67
EPS Next 2Y14.79%
EPS Next 3Y14.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EW Dividend Analysis

5.1 Amount

  • No dividends for EW!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EW Fundamentals: All Metrics, Ratios and Statistics

EDWARDS LIFESCIENCES CORP

NYSE:EW (4/23/2026, 3:48:09 PM)

79.76

-1.77 (-2.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)04-23
Inst Owners92.06%
Inst Owner Change-0.05%
Ins Owners0.09%
Ins Owner Change-2.52%
Market Cap45.98B
Revenue(TTM)6.07B
Net Income(TTM)1.07B
Analysts79.53
Price Target98.15 (23.06%)
Short Float %1.74%
Short Ratio2.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.39%
Min EPS beat(2)-8.84%
Max EPS beat(2)9.63%
EPS beat(4)3
Avg EPS beat(4)2.32%
Min EPS beat(4)-8.84%
Max EPS beat(4)9.63%
EPS beat(8)5
Avg EPS beat(8)1.48%
EPS beat(12)5
Avg EPS beat(12)0.35%
EPS beat(16)7
Avg EPS beat(16)-0.13%
Revenue beat(2)1
Avg Revenue beat(2)-0.31%
Min Revenue beat(2)-1.47%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.85%
Revenue beat(8)1
Avg Revenue beat(8)-2.84%
Revenue beat(12)2
Avg Revenue beat(12)-2.11%
Revenue beat(16)2
Avg Revenue beat(16)-2.28%
PT rev (1m)0.72%
PT rev (3m)0.16%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)5.99%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)1.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.81%
Valuation
Industry RankSector Rank
PE 31.16
Fwd PE 26.47
P/S 7.58
P/FCF 34.45
P/OCF 28.83
P/B 4.45
P/tB 6.18
EV/EBITDA 23.31
EPS(TTM)2.56
EY3.21%
EPS(NY)3.01
Fwd EY3.78%
FCF(TTM)2.32
FCFY2.9%
OCF(TTM)2.77
OCFY3.47%
SpS10.52
BVpS17.93
TBVpS12.91
PEG (NY)1.76
PEG (5Y)4.67
Graham Number32.1371 (-59.71%)
Profitability
Industry RankSector Rank
ROA 7.84%
ROE 10.38%
ROCE 13.87%
ROIC 12.01%
ROICexc 18.64%
ROICexgc 29.98%
OM 27.17%
PM (TTM) 17.69%
GM 78.01%
FCFM 22%
ROA(3y)18.26%
ROA(5y)18.16%
ROE(3y)24.41%
ROE(5y)25.04%
ROIC(3y)13.04%
ROIC(5y)15.54%
ROICexc(3y)18.54%
ROICexc(5y)20.56%
ROICexgc(3y)28.25%
ROICexgc(5y)29.44%
ROCE(3y)15.07%
ROCE(5y)17.95%
ROICexgc growth 3Y0.42%
ROICexgc growth 5Y-1.8%
ROICexc growth 3Y-6.11%
ROICexc growth 5Y-3.98%
OM growth 3Y-8.34%
OM growth 5Y-1.77%
PM growth 3Y-19.64%
PM growth 5Y-1.18%
GM growth 3Y-2.35%
GM growth 5Y0.69%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.45
Debt/EBITDA 0.33
Cap/Depr 166.16%
Cap/Sales 4.29%
Interest Coverage 81.62
Cash Conversion 88.36%
Profit Quality 124.36%
Current Ratio 3.72
Quick Ratio 3.09
Altman-Z 11.12
F-Score6
WACC8.86%
ROIC/WACC1.36
Cap/Depr(3y)177.3%
Cap/Depr(5y)193.25%
Cap/Sales(3y)4.93%
Cap/Sales(5y)5.41%
Profit Quality(3y)58.49%
Profit Quality(5y)66.28%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.29%
EPS 3Y1.06%
EPS 5Y6.67%
EPS Q2Q%-1.69%
EPS Next Y17.69%
EPS Next 2Y14.79%
EPS Next 3Y14.05%
EPS Next 5Y12.89%
Revenue 1Y (TTM)10.86%
Revenue growth 3Y10.77%
Revenue growth 5Y6.7%
Sales Q2Q%13.26%
Revenue Next Year10.66%
Revenue Next 2Y10.24%
Revenue Next 3Y10.15%
Revenue Next 5Y9.72%
EBIT growth 1Y11.04%
EBIT growth 3Y1.54%
EBIT growth 5Y4.82%
EBIT Next Year25.82%
EBIT Next 3Y16.1%
EBIT Next 5Y14.45%
FCF growth 1Y413.66%
FCF growth 3Y11.88%
FCF growth 5Y15.59%
OCF growth 1Y194.16%
OCF growth 3Y9.4%
OCF growth 5Y8.64%

EDWARDS LIFESCIENCES CORP / EW Fundamental Analysis FAQ

What is the fundamental rating for EW stock?

ChartMill assigns a fundamental rating of 7 / 10 to EW.


Can you provide the valuation status for EDWARDS LIFESCIENCES CORP?

ChartMill assigns a valuation rating of 5 / 10 to EDWARDS LIFESCIENCES CORP (EW). This can be considered as Fairly Valued.


Can you provide the profitability details for EDWARDS LIFESCIENCES CORP?

EDWARDS LIFESCIENCES CORP (EW) has a profitability rating of 8 / 10.


How financially healthy is EDWARDS LIFESCIENCES CORP?

The financial health rating of EDWARDS LIFESCIENCES CORP (EW) is 9 / 10.